drugset / Trial / NCT02638896
Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the efficacy of safety of etanercept dose reduction combined with sulfasalazine in ankylosing spondylitis (AS) patients who have achieved a significant clinical response.
Timeline
- Start
- 2016-01
- Primary completion
- 2017-02
- Completion
- 2017-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | 50 mg | Subcutaneous |
| Background | Celecoxib | Other / unclassified | 0.4 g | — |
| Background | Sulfasalazine | Small molecule | 2 g | Oral |